Navigation Links
InterMune Reports Presentation of Triple Combination Study of ITMN-191 at European Association for the Study of the Liver (EASL)
Date:4/24/2009

ITMN-191 was generally safe and well tolerated. There were no serious adverse events (SAE) or Grade 4 adverse events (AEs) during treatment with ITMN-191. AEs reported during study treatment (ITMN-191 or placebo) were predominantly mild to moderate in severity, typically consistent with the well-described AE profile of standard of care (SOC) and none led to treatment discontinuation.

Only four Grade 3 AEs were reported during study treatment, two of which (sciatica and back pain) were deemed by the investigator to be unrelated to ITMN-191. The other two were neutropenia and indirect bilirubin elevation. Neutropenia occurred with a similar pattern, frequency and severity in the placebo and ITMN-191 groups. Minor and transient elevations in indirect bilirubin levels were observed in a small number of placebo and ITMN-191 patients and were deemed not clinically significant by the investigator. There were no other laboratory or ECG findings during study treatment that were attributable to ITMN-191.

Phase 1b Triple Combination Trial Design

The Phase 1b randomized, double-blind, placebo-controlled, 14-day triple combination study was conducted in treatment-naive patients chronically infected with HCV genotype 1. The study objectives were to assess the safety, pharmacokinetic and viral kinetic effects of various doses and regimens of ITMN-191 for 14 days in combination with Pegasys and Copegus compared to treatment with Pegasys and Copegus alone. Patient follow-up continued for 30 days following the completion of study treatment.

INFORM-1 Program

In November 2008, Roche, InterMune and Pharmasset initiated the first all-oral combination study of direct-acting antivirals (DAAs) in the absence of interferon or ribavirin, known as the INFORM-1 study. Interim results from the INFORM-1 study will be presented in an oral late-breaker session of the EASL meeting on Satur
'/>"/>

SOURCE InterMune, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. InterMune Announces Approval of Clinical Trial Authorization for Phase 1b Trial of ITMN-191
2. InterMune Announces Start of Phase 1b Trial of ITMN-191
3. InterMune Announces Top-Line Results of Phase 1b Trial of ITMN-191 (R7227) and Provides Program Update
4. InterMune Provides Additional Information on ITMN-191 (R7227) MAD Study Results
5. InterMune Announces Progress on Pirfenidone in IPF
6. InterMune Announces Receipt of Fast Track Designation for Pirfenidone From FDA
7. InterMune Announces Start of 14-Day Triple Combination Study of ITMN-191 in Patients With Chronic Hepatitis C
8. Roche, InterMune and Pharmasset Announce Initiation of INFORM-1, the First Dual-Combination Clinical Trial with Oral Antivirals in Hepatitis C
9. InterMune to Report Top-Line Results of Triple Combination Study of ITMN-191 in January 2009
10. InterMune to Conduct Conference Call and Webcast to Discuss Results of Triple Combination Study of ITMN-191
11. InterMune to Announce Results of Phase 3 CAPACITY Program of Pirfenidone in IPF Tomorrow, February 3
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2015)... BUENA, N.J. , April 24, 2015  IGI ... Jersey based specialty generic pharmaceutical company, announced ... pm ET on Tuesday, April 28, 2015 to discuss ... invites you to listen to the call by dialing ... call 1-855-669-9657.  Participants should ask to be joined into ...
(Date:4/24/2015)...   Vestagen Technical Textiles, Inc. today announced ... recently received two notable innovation awards. The first is ... innovations with potential to create a positive impact in ... New York City , VESTEX received the ... Safety" category. The awards honor excellence in new product ...
(Date:4/24/2015)... and Markets ( http://www.researchandmarkets.com/research/pmbmv2/global_biobanking ) has announced ... report to their offering. The analysts ... CAGR of 7.07% over the period 2014-2019 ... segments: Equipment and Consumables. This report covers the present ... market for the period 2015-2019. ...
Breaking Medicine Technology:VESTEX Wins Innovation Honors from Edison Awards & Apparel Magazine 2VESTEX Wins Innovation Honors from Edison Awards & Apparel Magazine 3Global Biobanking Market Report 2015-2019 - Increase in Strategic Collaborations with Beckman Coulter, Tecan & Thermo Fischer Scientific Dominating 2
... (vRad), a technology-enabled national radiology practice, announced today ... been selected by Abbeville Area Medical Center (AAMC), ... AAMC selected vRad,s Enterprise Connect(SM), ... that was developed by radiologists for radiologists. The ...
... Royal Philips Electronics (AEX: PHI, NYSE: PHG ) ... (FFDM) solution, at four customer sites in North America, bringing ... system is on display at the 97th annual meeting of ... December 2. Mammography is the primary tool used ...
Cached Medicine Technology:vRad Selected by Abbeville Area Medical Center for PACS Replacement 2vRad Selected by Abbeville Area Medical Center for PACS Replacement 3Philips MicroDose Next Generation Mammography Solution Gains Traction with First North American Customers, Enabling Excellent Image Quality at a Low Radiation Dose 2Philips MicroDose Next Generation Mammography Solution Gains Traction with First North American Customers, Enabling Excellent Image Quality at a Low Radiation Dose 3
(Date:4/24/2015)... Vancouver, BC (PRWEB) April 24, 2015 ... Albert Yuzpe, Olive Fertility co-founder and co-director, has been ... Fertility Preservation at the Evening of Hope Gala. ... to recognize Dr. Albert Yuzpe, who has been at ... past 43 years,” says Jessica Séguin, Executive Director of ...
(Date:4/24/2015)... April 24, 2015 National Access ... and legal access to medical cannabis, is taking a ... supported when advising patients. , NAC is the first ... With a $250,000 grant, NAC will be providing 300 ... "Our goal is to help Canadians gain safe and ...
(Date:4/24/2015)... April 24, 2015 Telematics Berlin is ... automakers, tier 1 & 2 suppliers, content providers, associations ... players in the value chain, see them converge in ... not only hear from those companies currently at the ... future partners. Working on customer centric products, ParkTAG are ...
(Date:4/24/2015)... PURE Solutions, a leader in allergy travel ... Network), a highly respected education, advocacy and community out-reach ... information for a special allergy travel section ... goal for both organizations is to “make lives better” ... with asthma and allergies and by finding effective ways ...
(Date:4/24/2015)... (PRWEB) April 24, 2015 ProTube Outro is ... Pro X video editors. ProTube Outro allows editors to ... 5 video drop zones. Position, scale, and rotate pictures/videos, ... ProTube Outro uses simple borders and shadows for a ... exclusive plugin. , ProTube Outro comes packed with over 30 ...
Breaking Medicine News(10 mins):Health News:Olive Fertility Centre Co-founder, Dr Al Yuzpe, Recognized as a Pioneer in Fertility Preservation 2Health News:National Access Cannabis Gives 300 Canadian Healthcare Professionals Access to Medical Cannabis Certificate Program 2Health News:Telematics Berlin 2015’s inaugural European Automotive Start-Up Competition 2Health News:Telematics Berlin 2015’s inaugural European Automotive Start-Up Competition 3Health News:PURE Solutions Partners with Allergy and Asthma Network to Provide Allergy Travel Tips 2Health News:Pixel Film Studios, FCPX Plugin Developer Announced the Release of Protube Outro, Outro Screen Templates for Final Cut Pro X 2
... sexually transmitted infections to tell their partners// to seek ... or drugs to help reduce infection rates, says a ... an important part of managing most curable sexually transmitted ... often makes this difficult. ,Researchers analysed ...
... is in the process of doing away with a commonly ... phase out the ‘Aropax’ brand of paroxetine and bring in ... used by about 49,000 New Zealanders. ,This move ... maintains that both drugs are the same, except for the ...
... supplements of folic acid could improve the memory and ... researchers from the University of Wageningen gave a group ... acid supplements or a dummy drug for three years, ... ,The folic acid group had significantly better memories and ...
... are helping to lead a large international study // ... in an effort to determine whether exercise really is ... promoted the value of exercise for a variety of ... established as safe in the group of patients who ...
... light of new information on facial transplantation—including the psychological ... of the Royal College of Surgeons of England now ... according to a report published in the Jan. 27 ... in 2003, the Working Party concluded that facial transplantation ...
... It’s no secret why we shed tears. But exactly what our ... ,A new study sheds some light on the complex design ... film, which is made up of three distinct, microscopic layers. The ... when we cry – is sandwiched between a layer of mucus ...
Cached Medicine News:Health News:New International Study to Test Exercise in Heart Failure Patients 2Health News:New International Study to Test Exercise in Heart Failure Patients 3Health News:Royal College Issues Revised Guidelines for Face Transplantation 2Health News:Royal College Issues Revised Guidelines for Face Transplantation 3Health News:Tears Reveal Some of Their Deepest Secrets to Researchers 2Health News:Tears Reveal Some of Their Deepest Secrets to Researchers 3
Inquire...
Stainless steel construction to withstand sterilization modalities (EtO, Steris, and Sterrad) Wide angle of view...
ENDOlap™ laparoscopes provide excellent image linearity and flatness of field....
Superior imaging through a 410,000 pixel CCD, unseen color replication from a digital signal processor in the scope, and the added benefit of four way tip deflection make the TF410 a superior choice ...
Medicine Products: